


CLAIMS

1. A compound of general formula (I)



I

wherein

- 5 R^1 , R^2 , R^3 and R^4 are independently hydrogen, halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6 alkyl), $-CON(R^9)_2$, $-SOR^9$, $-SO_2R^9$, $-SO_2N(R^9)_2$, $-N(R^9)_2$, $-NR^9COR^9$, $-CO_2R^9$, $-COR^9$, $-SR^9$, $-OH$, $-NO_2$ or $-CN$;

each R^9 is independently hydrogen or C_1 - C_6 alkyl;

R^5 and R^6 are each independently hydrogen, or C_1 - C_6 alkyl or together with the carbon atom to which they are attached form a C_3 - C_7 cycloalkyl group;

R^7 is hydrogen or C_1 - C_6 alkyl

- 15 n is 1 or 2;

X is a bond or, when n is 2, X may also be a NR^9 group;

wherein R^9 is as defined above;

when X is a bond R^8 is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, biphenyl or a 9-14 membered bicyclic or tricyclic heteroaryl group;

- 20 when X is a NR^9 group R^8 may additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and

- the R^8 group is optionally substituted with one or more substituents selected from
halo, C_1 - C_6 alkyl, $-O(C_1$ - C_6)alkyl, aryl, $-O$ -aryl, heteroaryl, $-O$ -heteroaryl,
25 $-CON(R^9)_2$, $-SOR^9$, $-SO_2R^9$, $SO_2N(R^9)_2$, $-N(R^9)_2$, $-NR^9COR^9$, $-CO_2R^9$, $-COR^9$, $-SR^9$,


-OH, -NO₂ or -CN;

wherein R⁹ is as defined above;

or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.

5

2. A compound of general formula (II):



II

10 wherein R¹, R², R³, R⁴, R⁵, R⁶, n, X, R⁷ and R⁸ are as defined for general formula (I);
R¹⁰ is C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹¹)₂,
CH((CH₂)_mO(C=O)R¹²)₂;

m is 1 or 2;

R¹¹ is hydrogen or methyl;

15 R¹² is C₁-C₁₈ alkyl.

3. A compound as claimed in claim 1 or claim 2 wherein, independently or in any combination:

R¹ is halo or hydrogen;

20 R² is halo or hydrogen;

R³ is halo or hydrogen;

R⁴ is halo or hydrogen.

4. A compound as claimed in any one of claims 1 to 3 wherein R¹, R³ and R⁴ are
25 hydrogen and R² is halo.

5. A compound as claimed in claim 4 wherein R^2 is fluoro.
6. A compound as claimed in any one of claims 1 to 5 wherein R^5 and R^6 are
5 each independently hydrogen or C_1 - C_4 alkyl.
7. A compound as claimed in claim 6 wherein at least one of R^5 and R^6 are hydrogen.
- 10 8. A compound as claimed in claim 7 wherein both R^5 and R^6 are hydrogen.
9. A compound as claimed in any one of claims 1 to 8 wherein R^7 is H or C_1 - C_6 alkyl.
- 15 10. A compound as claimed in claim 9 wherein R^7 is methyl.
11. A compound as claimed in any one of claims 1 to 10 wherein n is 2.
12. A compound as claimed in any one of claims 1 to 11 wherein X is a bond and
20 R^8 is C_1 - C_6 alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl, $-CO_2R^9$, $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is as defined above.
13. A compound as claimed in claim 12 wherein R^8 is C_1 - C_4 alkyl, biphenyl, a
25 bicyclic heteroaryl group or a 5-7 membered heterocyclic ring, any of which may be substituted with phenyl, $-CO_2R^9$, $CON(R^9)_2$ or $-SO_2R^9$, where R^9 is H or C_1 - C_4 alkyl.
14. A compound as claimed in any one of claims 1 to 11 wherein X is NR^9 , R^9 is H or methyl and R^8 is:
30 phenyl optionally substituted with one or more halo, C_1 - C_6 alkyl or $-O(C_1$ - C_6 alkyl) groups;

C₁-C₆ alkyl, optionally substituted with aryl; or
heteroaryl.

15. A compound as claimed in claim 14, wherein R⁸ is phenyl, benzyl or pyridyl,
5 any of which may optionally be substituted with one or more halo, methyl or
methoxy groups.
16. [3-(Butane-1-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
3-(Biphenyl-4-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
10 [3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
(3-Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
[5-Fluoro-3-(2-methanesulfonyl-ethanesulfonyl)-2-methyl-indol-1-yl]-acetic acid
[3-(Benzothiazole-2-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(Benzothiazole-2-sulfinyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
15 [5-Fluoro-2-methyl-3-(quinoline-2-sulfonyl)-indol-1-yl]-acetic acid
[5-Fluoro-2-methyl-3-(quinolin-8-ylsulfonyl)-indol-1-yl]-acetic acid
(5-Fluoro-2-methyl-3-phenylmethanesulfonyl-1H-indol-1-yl)-acetic acid
[3-(4-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(3-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
20 [3-(4-Fluoro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(2-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
(3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
[5-Fluoro-3-(2-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-3-(4-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
25 (5-Fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl)-acetic acid
[3-(3,4-Dichloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-3-(3-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
(5-Fluoro-2-methyl-3-*m*-tolylsulfamoyl-indol-1-yl)-acetic acid
(5-Fluoro-2-methyl-3-*p*-tolylsulfamoyl-indol-1-yl)-acetic acid
30 [3-(4-Chloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(Benzyl-methyl-sulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[5-Fluoro-2-methyl-3-(pyridin-3-ylsulfamoyl)-indol-1-yl]-acetic acid;

or the C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹¹)₂,
CH((CH₂)_mO(C=O)R¹²)₂ esters of any of the above; wherein

m is 1 or 2;

5 R¹¹ is hydrogen or methyl;

R¹² is C₁-C₁₈ alkyl.

17. A process for the preparation of a compound of general formula (I) as
claimed in any one of claims 1 to 13 or 16 wherein n is 1 or 2 and X is a bond, the
10 process comprising treating a compound of general formula (Ia), which is a
compound of general formula (I) wherein n is 0 and X is a bond, by oxidation with a
suitable oxidising agent.

18. A process for the preparation of a compound of general formula (I) as
15 claimed in any one of claims 1 to 16, the process comprising reacting a compound of
general formula (II) as defined in claim 2 and wherein R¹⁰ is C₁-C₆ alkyl with a base.

19. A compound as claimed in any one of claims 1 to 16 for use in medicine.

20. 20. A compound as claimed in any one of claims 1 to 16 for use in the treatment
of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic
dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis,
especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic
gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease,
25 mastocytosis, another PGD₂-mediated disease, for example autoimmune diseases
such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne,
multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive
pulmonary disease; or rheumatoid arthritis, psoriatic arthritis or osteoarthritis.

30 21. The use of a compound as claimed in any one of claims 1 to 16 in the
preparation of an agent for the treatment or prevention allergic asthma, perennial

allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, another PGD₂-mediated disease, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive pulmonary disease; or rheumatoid arthritis, psoriatic arthritis or osteoarthritis.

22. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 16 together with a pharmaceutical excipient or carrier.

23. A composition as claimed in claim 22 formulated oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

24. A composition as claimed in claim 23 formulated for oral, nasal, bronchial or topical administration.

25. A composition as claimed in any one of claims 22 to 24 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

26. A composition as claimed in claim 25, wherein the additional active agents are selected from:

β₂ agonists such as salmeterol;

corticosteroids such as fluticasone;

antihistamines such as loratidine;

leukotriene antagonists such as montelukast;

anti-IgE antibody therapies such as omalizumab;

anti-infectives such as fusidic acid (particularly for the treatment of atopic

dermatitis);

anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis);
immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of
inflammatory skin disease;

- 5 other antagonists of PGD_2 acting at other receptors such as DP antagonists;
inhibitors of phosphodiesterase type 4 such as cilonilast;
drugs that modulate cytokine production such as inhibitors of $\text{TNF}\alpha$ converting
enzyme (TACE);
drugs that modulate the activity of Th2 cytokines IL-4 and IL-5 such as blocking
10 monoclonal antibodies and soluble receptors;
PPAR- γ agonists such as rosiglitazone;
5-lipoxygenase inhibitors such as zileuton.

27. A process for the preparation of a pharmaceutical composition as claimed in
15 any one of claims 22 to 26 comprising bringing a compound as claimed in any one of
claims 1 to 16 in conjunction or association with a pharmaceutically or veterinarily
acceptable carrier or vehicle.

28. A product comprising a compound as claimed in any one of claims 1 to 16
20 and one or more of the agents listed in claim 26 as a combined preparation for
simultaneous, separate or sequential use in the treatment of a disease or condition
mediated by the action of PGD_2 at the CRTH2 receptor.

29. The use as claimed in claim 21, wherein the agent also comprises an
25 additional active agent useful for the treatment of diseases and conditions mediated
by PGD_2 at the CRTH2 and/or DP receptor.

30. The use as claimed in claim 29, wherein the additional active agent is one of
the agents listed in claim 26.